The winner and loser of the long patent suit were reversed in the end. After losing the first and second trial, BMS finally got the upper hand in the fight with the generic manufacturers with a favorable ruling by the supreme court.

On the other side, the generic companies are in hot water due to the unexpected result. In addition to immediately discontinuing the sale of its generics, the companies are expecting a massive damages claim will be filed by the original drug’s company.

The ruling will also affect the price cut that was previously ordered for Eliquis. If the ruling is finalized, the price cut disposition will be pushed back to the patent expiry date.

#s